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Abstract
FUS1 is a tumor suppressor gene located on human chromosome 3p21, and expression of Fus1
protein is highly regulated at various levels, leading to lost or greatly diminished tumor suppressor
function in many lung cancers. Here we show that selected microRNAs (miRNAs) interact with the
3’ untranslated region (3’ UTR) of FUS1, leading to down-regulation of protein expression. Using
computational methods, we first predicted that FUS1 is a target of three miRNAs, miR-93, miR-98
and miR-197, and then showed that exogenous over-expression of these miRNAs inhibited Fus1
protein expression. We then confirmed that the three miRNAs target the 3’UTR region of the
FUS1 transcript, and that individual deletion of the three miRNA target sites in the FUS1 3’UTR
restores the expression level of Fus1 protein. We further found that miR-93 and miR-98 are expressed
at higher levels in small cell lung cancer cell lines (SCLC) than in non-small cell lung cancer cell
lines (NSCLC) and immortalized human bronchial epithelial cells (HBECs), and that miR-197 is
expressed at higher levels in both SCLC and NSCLC than in HBECs. Finally, we found that elevated
miR-93 and miR-197 expression is correlated with reduced Fus1 expression in NSCLC tumor
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specimens. These results suggest that the three miRNAs are negative regulators of Fus1 expression
in lung cancers.
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Introduction
FUS1, also known as TUSC2 (tumor suppressor candidate 2), is a tumor suppressor gene
located on human chromosome 3p21.3, a region in which deficient gene expression is
frequently seen in lung cancer (1). The tumor suppressor function of Fus1 has been
demonstrated in studies showing that over-expression of Fus1 significantly inhibits tumor
growth and progression in mouse models (2), and that FUS1 knockout mice show an increased
frequency of spontaneous cancers (3). More recently, Prudkin et al. found a reduction or
complete loss of Fus1 expression in 82% of NSCLCs and 100% of SCLCs studied, which was
associated with significantly worse overall survival (4), further demonstrating that Fus1 plays
an important role in the pathogenesis of lung cancer.
Loss or reduced FUS1 expression could be caused by various mechanisms. Allelic loss of the
3p21.3 chromosomal region containing FUS1 is the major cause of loss or reduction of Fus1
expression in lung cancer (1,5). In other cases, however, the FUS1 gene and FUS1 mRNA
expression level are normal, but the Fus1 protein is not expressed at detectable levels (1,6),
suggesting that Fus1 expression may be down-regulated at certain post-transcriptional stages.
One mechanism regulating FUS1 expression and function has already been shown by Uno et
al., who demonstrated that loss of myristoylation of Fus1 protein causes it to be rapidly
degraded and removes its ability to suppress tumor growth (7). Recent work on non-coding
RNAs suggests other mechanisms by which transcription and translation of FUS1 might also
be effectively uncoupled, including translational repression and destabilization of the FUS1
mRNA, both of which can be mediated by miRNAs.
miRNAs are short, 21 to 23 nucleotide RNAs that regulate gene expression by binding to
sequences in the 3’ untranslated region (3’ UTR) of an expressed mRNA, resulting in either
modulation of translation efficiency or degradation of the mRNA (8–10). miRNAs have been
shown to regulate expression of a variety of genes involved in embryonic development and in
human disease (8,11–21), including cancer (22–26). The 3’ UTR of FUS1 is highly conserved,
strongly suggesting that it plays an important role in regulating FUS1 expression. Target
prediction shows that at least 3 miRNAs — miR-93, miR-98 and miR-197 — potentially
interact with the FUS1 3’UTR. We therefore examined the role of these miRNAs in regulating
Fus1 protein expression.
Results
The 3’UTR of FUS1 plays a significant role in regulating FUS1 expression levels in NCI-H1299
cells
Previous studies have shown that Fus1 is expressed in normal lung epithelial cells, but the
expression is frequently reduced or lost in lung cancer cell lines and in lung cancer specimens
(4,7), despite the FUS1 mRNA being expressed in these cells. To assess the role of the 3’UTR
of FUS1 in regulating Fus1 protein expression, we compared the levels of expression of the
recombinant proteins from Flag-FUS1 (Flag-tagged FUS1 without the 3’UTR), and Flag-
FUS1-3’UTR (Flag-tagged FUS1 with the full-length 3’UTR) constructs. As shown in Figure
1A, 1B and 1C, both the mRNA and protein expression levels of Fus1 were significantly lower
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in cells expressing Flag-FUS1-3’UTR than in cells expressing Flag-FUS1 (p=0.0024 and
p=0.0019, n=5). mRNA expression levels of neo (Figure 1D), which was also present in the
expression vector and served as a control for expression efficiency of the vector (27), indicated
that the higher expression level of Fus1 protein in cells expressing Flag-FUS1 was not due to
higher expression efficiency of this construct relative to that of the Flag-FUS1-3’UTR. An
inverse relationship between exogenously induced over-expression of FUS1 and the growth
rate of H1299 cells has already been established (6). We therefore examined the contribution
of the 3’UTR of FUS1 to cell proliferation by colony formation assay. As shown in Figure 1E–
G, Flag-FUS1 expression significantly inhibited cell growth relative to Flag-FUS1-3’UTR and
the control vector, with the number and size of colonies formed in the presence of Flag-FUS1
much smaller than in the presence of Flag-FUS1-3’UTR (p=0.0081 and p=0.0011) or the vector
control (p=0.0048 and p=0.0004, by two-tailed paired t-test). Taken together, these results
implicate the 3’UTR of FUS1 in reducing levels of Fus1 expression and tumor suppressor
function.
miR-93, miR-98 and miR-197 are predicted to target the 3’UTR of FUS1
Using a program we developed (miRmate), we identified three miRNAs — miR-93, miR-98
and miR-197 — that are highly likely to interact with the 3’ UTR of FUS1. As shown in Figure
2A, the predicted target sites of miR-93 and miR-98 are located in regions that are highly
evolutionarily conserved, while the predicted target site of miR-197 does not fall in a highly
conserved region. Figure 2B shows the structure of the miRNA:target interactions for miR-93,
miR-98 and miR-197, with the conservation of the target sites across species. Both PicTar
(28) and TargetScan(29) also predict several miRNA target sites in the FUS1 3’UTR, including
those for miR-93 and miR-98.
miR-93, miR-98 and miR-197 translationally repress Fus1 by targeting specific sequences in
the 3’UTR of FUS1
In order to test the effect of the three miRNAs on Fus1 protein expression, we co-transfected
NCI-H1299 cells with the Flag-FUS1-3’UTR construct and with either control or miRNA
expression constructs. As shown in Figure 3A and 3B, over-expression of miR-93 or miR-98
significantly inhibited Fus1 protein expression (0.58±0.16 and 0.32±0.12 relative to control,
with p=0.0239 and p=0.0050, by one-tailed paired t-test, n=3), with miR-98 showing a greater
effect than miR-93. miR-197 does not significantly decrease Fus1 protein expression (0.89
±0.06 relative to control, with p=0.0515, n=3), although the over-expressed level of miR-197
relative to endogenous control is much higher than that of miR-93 and miR-98, as shown in
Figure 3E. FUS1 mRNA levels are not significantly affected by miRNA over-expression
(Figure 3C), and neo expression levels measured as a control for transfection efficiency are
not significantly different between samples (Figure 3D).
To test the specificity of the interaction between the three miRNAs and the 3’UTR of FUS1,
we placed the 3’UTR of FUS1 downstream of the luciferase coding region in an expression
construct. We co-expressed the reporter construct with either a vector expressing a candidate
miRNA, a control vector expressing miR-199b, which is not predicted to target the 3’UTR of
FUS1, or an empty vector (pCMV6), and monitored luciferase activity. As shown Figure 3F,
each miRNA repressed luciferase activity by 25–30%, as compared with the control. This
magnitude of repression is consistent with that observed in previous studies of miRNA
regulation using luciferase reporter vectors (28, 30).
To further confirm the specific target sites of the three miRNAs in the 3’UTR of FUS1, we
deleted the seed sequences of the miR-93, miR-98 and miR-197 target sites (Figure 2B) in the
3’UTR of the Flag-FUS1-3’UTR construct, and compared protein expression and tumor
suppressor function of FUS1 with that of the wildtype Flag-FUS1 and Flag-FUS1-3’UTR
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constructs in transfected NCI-H1299 cells. As shown in Figure 4A and 4B, individual deletions
of the seed sequences of the miR-197, miR-93, and miR-98 target sites significantly increased
the expression level of Fus1 protein relative to wildtype Flag-FUS1-3’UTR (1.6 fold with
p=0.0477, 2 fold with p=0.0259, and 1.85 fold with p=0.0067, respectively, by one-tailed paired
t-test, n=4) with the combinatorial deletion showing higher levels of protein expression than
individual deletions (2.24 fold). Relative levels of FUS1 (Figure 4C) and neo mRNA (Figure
4D) measured by qRT-PCR were not altered by the deletions. As shown in Figure 4E–G, over-
expression of the Flag-FUS1-3’UTR expression constructs with individual deletions of the
miR-197, miR-93 and miR-98 seed target sequences as wells as combined deletion of the three
target sites significantly decreased the number (p=0.0012, p=0.0328, p=0.0036 and p=0.0024,
respectively, by one-tailed paired t-test, n=3) and size (p=0.0044, p=0.0500, p=0.0083 and
p=0.0101, respectively, by one-tailed paired t-test, n=3) of the colonies formed as compared
with wildtype Flag-FUS1-3’UTR construct. The above results indicate that removal of the
three miRNAs target sites in the 3’UTR of FUS1 significantly restores Fus1 protein expression,
and correspondingly, restores its function as a tumor suppressor.
Overall, these results indicate that miR-93, miR-98 and miR-197 negatively regulate FUS1
tumor suppressor function by inhibiting Fus1 protein expression through targeting specific
sites in the FUS1 3’UTR.
miR-93 and miR-98 are expressed at higher levels in SCLC than in NSCLC and HBEC cell
lines, and miR-197 is expressed at higher levels in both SCLC and NSCLC relative to HBEC
cell lines
To evaluate the physiological relevance of these miRNAs in lung cancer pathogenesis, we
analyzed endogenous expression levels of these three miRNAs in 9 SCLC cell lines, 8 NSCLC
cell lines, and 3 immortalized normal human bronchial epithelial cell lines (HBECs). We
profiled expression levels of 136 miRNAs in these cell lines in duplicate using miRNA
microarrays. The normalized expression profiles allowed us to identify miRNAs with
statistically significant differential expression between SCLC and NSCLC cell lines and
between lung cancer cell lines and HBECs. We found that miR-93 and miR-98 are over-
expressed in SCLCs relative to NSCLC and HBECs, and miR-197 is over-expressed in both
SCLCs and NSCLC relative to HBECs. As shown in Figure 5A and 5B, the expression levels
of miR-93, miR-98 and miR-197 differ significantly among the different cell lines, and
generally miR-93 and miR-98 are expressed at higher levels in SCLC (n=9) as compared with
NSCLC (1.88 fold with p=0.0001 by two-tailed t-test, and 3.04 fold with p<0.0001, n=8) and
HBECs (1.98 fold with p=0.0100, and 2.50 fold with p=0.0077, n=3), whereas miR-197 is
expressed at higher levels in both SCLCs and NSCLCs as compared with HBECs (2.07 fold
with p=0.0060, and 1.84 fold with p=0.0206). This suggests that aberrant expression of
miR-197 might contribute to both SCLC and NSCLC tumorigenesis in general, while miR-93
and miR-98 may play a more important role in the development of SCLCs than NSCLCs.
Expression of miR-93 and miR-197 is inversely correlated with Fus1 expression in lung
cancer tumor specimens
Levels of all three miRNAs differ dramatically between the NSCLC cell lines, suggesting that
aberrant expression of the miRNAs may contribute to the decrease of Fus1 expression in
specific NSCLCs. In order to examine the correlation of the three miRNAs with Fus1 level,
we measured the expression levels of miR-93, miR-98 and miR-197 in 20 NSCLC tumor
specimens (14 adenocarcinoma and 6 squamous cell carcinoma) samples by qRT-PCR. These
samples had been previously characterized as positive for Fus1 expression by
immunohistochemical staining (4) and were classified into two groups, “low” and “high”,
based on Fus1 expression. As shown in Figure 6A, expression of miR-93 and miR-197 is
significantly higher in samples in the “low” Fus1 group than in the “high” Fus1 group (1.62
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fold with p=0.0164, and 1.48 fold with p=0.0265 by one-tailed t-test with n=10), while
expression of miR-98 is not significantly different between the two groups (p=0.3390, n=10).
In contrast, expression levels of miR-205 and miR-338, which are not predicted to target
FUS1 mRNA, are not significantly different between the two groups (p=0.4961 and p=0.4318),
as shown in Figure 6B.
Discussion
The 3’UTRs of many protein-coding mRNAs have been shown to play an important role in
regulating protein expression. Regulatory elements typically located in 3’UTRs include AU-
rich elements (ARE) and iron-response elements (IREs) (31). Binding of the trans-acting
factors ARE binding proteins (ARE-BP) and IRE binding proteins (IRE-BP) to AREs and
IREs, respectively, leads to either translational repression/enhancement or mRNA
stabilization/destabilization. In this study, we show that the 3’UTR significantly represses the
expression of FUS1 at both the mRNA and protein levels. Analysis of the FUS1 3’UTR shows,
however, that it lacks typical ARE and IRE elements, suggesting a different regulatory
mechanism. Using computational methods, we predicted that the 3’UTR of FUS1 contains
target sites of at least three miRNAs, including miR-93, miR-98 and miR-197. We showed
that deletion of the seed sequences of the miRNA target sites in the 3’UTR significantly restores
protein expression levels (Figure 4A) and, correspondingly, the tumor suppressor function of
FUS1 (Figure 4E–G), suggesting that Fus1 expression is under significant repression by
endogenous expression of the three miRNAs.
In order to confirm the direct interaction of the miRNAs with the 3’UTR of FUS1, we conducted
luciferase reporter assays in HEK 293 cells. Our results (Figure 3F) show that for miR-197,
both a 1:1 ratio and a 5:1 ratio of miRNA vector to luciferase reporter vector result in the
maximum reduction of the luciferase activity. For miR-93 and miR-98, however, a 1:1 ratio
of miRNA expression vector to luciferase reporter vector is not enough to significantly inhibit
luciferase activity, and a 5:1 ratio is needed to reach the maximum effect. These data indicate
that the 3’UTR of FUS1 is more sensitive to lower doses of miR-197 than of miR-93 and
miR-98, which suggests that miR-197 might have a more substantial direct effect on the 3’UTR
of FUS1 than do miR-93 and miR-98. However, when over-expressing the three miRNAs in
NCI-H1299 cells, miR-93 and miR-98 significantly inhibited Fus1 protein expression, whereas
unexpectedly, miR-197 did not have a significant inhibitory effect (Figure 3A). The following
possibilities could lead to the above outcome: 1) miR-197 regulates Fus1 expression through
both direct and indirect mechanisms. In H1299 cells, miR-197 might inhibit the expression of
another gene that down-regulates Fus1 expression. The resulting down-regulation of this gene
will compensate for the direct inhibitory effect of miR-197 on the 3’UTR of FUS1. If both
pathways are active in H1299 cells, then over-expression of miR-197 in H1299 would not
significantly decrease Fus1 expression due to the opposing directions of these two regulatory
pathways. 2) In H1299 cells, but not in HEK293 cells, the 3’UTR of FUS1 is maximally
repressed by endogenous miR-197, so that exogenous introduction of miR-197 cannot lead to
further significant inhibition of Fus1 expression (Figure 3A). In this case, removal of the
miR-197 target site would release FUS1 from repression by endogenous miR-197, leading to
the observed significant increase in Fus1 protein (Figure 4A and 4B).
As for the role of the 3’UTR in regulating FUS1 mRNA levels, our results indicate that the
3’UTR is responsible not only for decreasing expression of the Fus1 protein product, but also
for significantly down-regulating mRNA expression (Figure 1A and 1C). On the other hand,
our results (Figure 3C and Figure 4C) also show that the three miRNAs do not significantly
affect FUS1 mRNA levels. The above results clearly indicate that there are additional undefined
site(s) in the 3’UTR of FUS1 that influence mRNA stability. However, combined removal of
the three miRNA target sites restores protein expression nearly completely (Figure 4A). This
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result not only suggests that the low levels of FUS1-3’UTR mRNA can be translated very
efficiently upon removal of the miRNA target sites, but also seems to imply that mRNA
stability (as reflected in mRNA levels) does not play a significant role in controlling Fus1
protein levels. We speculate that the disruption of only the mRNA de-stabilizing site(s) would
significantly increase both the FUS1 mRNA and protein level. It is also reasonable to infer,
however, that the removal of both the miRNA regulatory sites and the mRNA de-stabilizing
sites altogether (by removing the 3’UTR as shown in Figure 4A) could not bring the Fus1
protein to a significantly higher level than what would be observed after removing either the
miRNA target sites or the mRNA de-stabilizing site(s), since the significantly elevated Fus1
protein level might induce more intensive down-regulation of Fus1 through a mechanism such
as protein degradation, thereby leading to lower than “predicted” Fus1 levels. These
possibilities suggest attractive future directions for studying the regulation of FUS1 mRNA
stability and Fus1 protein regulation at the post-translational level.
Of the three miRNAs that translationally repress Fus1, miR-93 and miR-98 are overexpressed
in SCLC relative to NSCLC and HBECs. This finding is of particular interest given the early
dissemination and rapid clinical evolution of SCLC relative to the slow clinical progression of
NSCLC. Coupled with the finding that average Fus1 expression is significantly lower in SCLC
tissue specimens than in NSCLC tissue specimens and normal lung epithelia (4), it is reasonable
to speculate that the overexpression of these two miRNAs in SCLC is one of the factors
contributing to the loss or reduction of Fus1 expression. miR-93 and miR-197 are expressed
at higher levels in specimens where Fus1 expression is low, and at lower levels in specimens
where Fus1 expression is high, suggesting that miR-93 and miR-197 are responsible, at least
partially, for the reduced Fus1 expression in the former. The expression of miR-98, however,
does not differ significantly between the two groups, possibly because the endogenous level
of miR-98 is not high enough to affect the Fus1 level in NSCLC tissue specimens, especially
in the presence of high levels of miR-93 and miR-197 in the specimens with low Fus1
expression. Overall, our results indicate that the expression of the three miRNAs is related to
Fus1 expression in lung cancer, suggesting that the aberrant expression of these miRNAs might
play a role during the tumorigenesis of lung cancer by regulating Fus1 expression.
miR-93 and miR-98 have been linked to cancer in previous studies. For example, Blenkiron
et al. recently showed that miR-93 expression is upregulated in primary breast cancer as
compared with normal breast cells (32). Yanaihara, et al. reported that over-expression of
miR-93 correlated with worse prognosis of lung adenocarcinoma patients (33). These studies,
however, did not investigate whether miR-93 has an oncogenic function. Our results thus
provide the first evidence that miR-93 acts as an oncogene by down-regulating the expression
of tumor suppressor gene FUS1. Hebert et al. showed that miR-98 targets Hmga2 in head and
neck squamous cell carcinoma (HNSCC) cells (34). Hmga2 expression has been linked to
several other types of cancers and has been shown to be associated with enhanced selective
chemosensitivity of cancer cells to the topoisomerase II inhibitor doxorubicin (35–37).
Interestingly, translocations frequently append the 3’UTR of HMGA2 to the 3’ end of tumor
suppressor genes such as FHIT, RAD51L1 and HEI10, suggesting that translational repression
of these tumor suppressor genes by miR-98 may contribute to tumorigenesis. Coupling these
results, we speculate that miR-98 may play a critical role in the development of cancer by
regulating expression of multiple cancer-related proteins, including Fus1. In contrast to miR-93
and miR-98, little is known about the function of miR-197. Our results therefore implicate
miR-197 in carcinogenesis through its down-regulation of Fus1 expression. Unlike miR-93
and miR-98, which are overexpressed in SCLC, miR-197 is overexpressed in both NSCLC
and SCLC relative to normal HBECs, suggesting that miR-197 plays a more important role in
down-regulating Fus1 expression in NSCLC than either miR-93 or miR-98.
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Overall, our results are the first demonstration that three miRNAs – miR-197, miR-93 and
miR-98 – down-regulate Fus1 expression by targeting the 3’UTR of FUS1, and also clearly
indicate that there are additional undefined site(s) in the 3’UTR of FUS1 that influence mRNA
stability. In addition, given the rapid growth of the miRNA family, it is reasonable to expect
that there are unknown miRNAs that regulate Fus1 expression. For example, recent work by
Lee et al. has shown that miR-378 can down-regulate Fus1 expression in U87 cells (38). Further
study is needed to define the full set of regulatory sites in the 3’UTR of FUS1 and of regulators
of Fus1 expression. From a clinical perspective, while our preliminary investigation in lung
cancer cell lines and clinical samples suggests that aberrant expression of these miRNAs plays
a role in down-regulating Fus1 expression, further investigation is needed to fully define their
role in the development and progression of lung cancer in vivo.
Materials and Methods
Cell lines
Lung cancer cell lines (NCI-H146, NCI-H157, NCI-H187, NCI-H209, NCI-H526, NCI-H889,
NCI-H1299, NCI-H1648, NCI-H1672, NCI-H1770, NCI-H1819, NCI-H2052, NCIH2107,
NCI-H2171, NCI-H2195, NCI-H2122, NCI-H2887, HCC366, HCC970, HCC1195, and
HCC2450) were from the Hamon Center collection. HEK-293 cells were obtained from ATCC
(Manassas, VA). Lung cancer cell lines and HBECs were grown in RPMI 1640 supplemented
with 5% FBS (Atlanta Biologicals, Lawrenceville, GA). HEK-293 cells were grown in
Dulbecco’s MEM (Mediatech, Manassas, VA) supplemented with 10% FBS.
Construction of expression vectors
miR-197, miR-93, and miR-98 and miR-199b were amplified by PCR from genomic human
DNA using the following primers:








The amplified sequences were inserted into the EcoRI and XmaI restriction sites of the multiple
cloning site of expression vector pCMV6 and verified by sequencing. To investigate the
regulation of Fus1 by miRNAs, we added a Flag tag to the N-terminus of Fus1 and made three
derivative constructs: Flag-FUS1, Flag-FUS1-3'UTR and Flag (as a negative control) based
on the pcDNA3.1 expression vector. We also made mutated constructs based on Flag-
FUS1-3'UTR with the miR-93, miR-98 and miR-197 seed sequences of the target sites deleted
individually and in combination. In order to test the interaction between specific miRNAs and
the 3’UTR of FUS1, the 1.2 kb 3’UTR was cloned into pMIR-REPORT (Ambion, Austin,
TX), a reporter construct containing a luciferase cDNA under the control of a mammalian
promoter/terminator system.
Du et al. Page 7














Cells were plated and cultured overnight. Cells were then transfected with specified expression
vectors using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) or FuGENE 6 Transfection
Reagent (Roche, Basel, Switzerland). After 48 hours, cells were harvested and specified assays
were conducted.
Luciferase Assay
Luciferase activity and β-galactosidase activity were measured using the Luciferase Assay
System and β-galactosidase Assay System (Promega, Madison, WI), respectively. Luciferase
activity was adjusted for transfection efficiency by normalizing by the β-galactosidase activity
of each sample.
Quantitative RT-PCR
Total RNA was prepared using the mirVana™ miRNA Isolation Kit (Ambion, Austin, TX)
followed by treatment with DNase. Quantitative RT-PCR (qRT-PCR) of miRNAs was
conducted on an ABI PRISM 7900 Sequence Detection System using TaqMan® Universal
PCR Master Mix and miRNA Expression Assay primer and probe sets (Applied Biosystems,
Foster City, CA). RNU19 RNA was used as an internal control for normalization of cDNA
loading. FUS1 and neo expression were measured using TaqMan® reverse transcription kits
with qRT-PCR conducted using TaqMan® Universal PCR Master Mix and Gene Expression
Assay primer and probe sets (Applied Biosystems). GAPDH mRNA was used as an internal
control for normalization of cDNA loading. Threshold cycle times (Ct) were obtained and
relative gene expression was calculated using the comparative cycle time method (39).
qRT-PCR in lung tumor samples
Four 20 µm sections were collected from each of 20 formalin-fixed paraffin-embedded (FFPE)
lung tumor tissue specimens (14 adenocarcinoma, 6 squamous cell carcinoma) previously
characterized for Fus1 expression by immunohistochemical staining (4). Deparaffinization,
digestion, and RNA isolation were performed using the RecoverAll™ Total Nucleic Acid
Isolation kit (Ambion, Austin, TX), according to manufacturer instructions. RNA
concentration and quality were assessed by spectrophotometer. miRNA expression was
measured using 10 ng of total RNA from each sample with TaqMan® microRNA Assays on
an ABI 7900HT Real Time PCR Instrument (Applied Biosystems). We used RNU19 as a
loading control and normalized all measurements to RNU19 levels. We determined the miRNA
expression levels using the absolute quantification method.
Western blots
Cells were washed with ice-cold phosphate buffered saline (PBS) and cell lysates prepared by
incubating cells in NP-40 buffer for 1 h on ice. Cell lysates were centrifuged at 13,000 rpm for
15 minutes at 4°C and the pellets were discarded. Protein concentration of the supernatant was
determined using the PIERCE BCA assay (PIERCE, Rockford, IL). For electrophoresis, equal
amounts of cell lysate protein (30 µg) were resolved by SDS-PAGE and transferred to
polyvinylidene difluoride (PVDF) membrane (Millipore, Billerica, MA). Flag-tagged Fus1
protein was detected by immunoblotting with mouse anti-Flag primary antibody (Sigma-
Aldrich, St. Louis, MO) followed by incubation with goat anti-mouse HRP-conjugated
secondary antibody (Santa Cruz Biotechnology, Santa Cruz, CA). Calnexin protein was
detected by immunoblotting with rabbit anti-calnexin primary antibody Stressgen
Biotechnologies, San Diego, CA) followed by incubation with goat anti-rabbit HRP-
conjugated secondary antibody (Santa Cruz Biotechnology). Bands were detected by exposing
the membrane to Kodak™ X-OMAT™ Blue XB-1 film (Eastman Kodak, Rochester, NY) for
1–2 minutes. Band intensities were quantitated using a Kodak™ Image Station 2000.
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Interactions between miR-197, miR-93 and miR-98 and the 3’UTR of FUS1 were predicted
by miRmate, a microRNA target prediction algorithm developed in our lab. The determinants
of the interaction between microRNAs and their target sites are believed to be (1) perfect
complementarity in the seed sequence (bases 2–8 of the miRNA), (2) a favorable free energy
of hybridization (ΔG ≈ −20–25 kcal/mol), and (3) accessibility of the target site in the 3’UTR.
Most target prediction methods include one or more of these, and often include evolutionary
conservation of the target site. miRmate considers complementarity (including the G·U
basepairing found in RNA duplexes), based on variable weighting of positions across the
miRNA, so as to encourage (but not require) complete complementarity at positions 2–8 of the
miRNA (the seed region) and mismatches and insertions in the central bulge at positions 9–11
of the miRNA. This allows strong complementarity at the 3’ end to compensate for suboptimal
complementarity at the 5’ end. This analysis is coupled with an estimate of the hybridization
free energy of the predicted mRNA-miRNA duplexes. Evolutionary conservation across
species is used post hoc to prioritize candidate target sites. Of the relatively small number of
experimentally validated miRNA:target pairs, miRmate correctly identifies more with lower
(better) rank fractions and misses fewer than other commonly used methods, including
TargetScan, miRanda and PicTar.
Colony formation assay
NCI-H1299 cells were plated in 100 mm dishes, grown for 24 h, and transfected with plasmids
pcDNA3.1/Flag, pcDNA3.1/Flag-FUS1, and pcDNA3.1/Flag-FUS1-3'UTR. After 48 h of
transfection, the cells were trypsinized, and 5,000 cells were replated in 10 cm dishes and
cultured in G418 (800 µg/ml) supplemented medium (RPMI 1640, 5% fetal bovine serum) for
2 weeks. Colonies were then stained with 1% crystal violet in ethanol/PBS (15%/85%).
miRNA expression profiling
Oligonucleotide probes for 136 nonredundant, conserved human and mouse miRNAs,
antisense to the published mature sequences, were synthesized and spotted in duplicate on
Corning GAPS-2 coated slides using a robotic spotter (40). RNA species smaller than 200 nt
were isolated from total RNA samples and labeled with a fluorescent modified dinucleotide
(5’-phosphate-cytidyl-uridyl-Cy3-3’) using T4 RNA ligase (40). Samples were hybridized to
the array along with an equimolar reference oligonucleotide set corresponding to all mature
miRNAs, which had been labeled with Cy5. The reference set allows normalization of different
datasets to a common standard and in principle allows measurement of absolute expression
levels. Array images were analyzed with GenePix Pro 4.1 (Molecular Devices, Sunnyvale,
CA). We measured raw Cy3/Cy5 ratios, which we log transformed, normalized by median
centering and clustered using average linkage hierarchical clustering based on Pearson
correlation.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. The 3’UTR plays a significant role in regulating Fus1 protein and mRNA expression levels
(A–D) We cloned constructs expressing either Flag-tagged FUS1 without the 3’UTR (Flag-
FUS1) or Flag-tagged FUS1 with the full length 3’UTR (Flag-FUS1-3’UTR). NCI-H1299 cells
were transfected for 48 h with either equal amounts (0.46 nM) of the above constructs, or were
treated with only transfection reagents (control). (A) The protein expression level of Fus1 was
detected by Western blot using an anti-Flag antibody, with calnexin as a loading control. (B)
Quantification results of the Fus1 protein level were from three independent experiments.
(C) The mRNA level of FUS1 as detected by quantitative PCR. (D) The mRNA level of neo
as detected by quantitative PCR. (E–G) Colony formation s a function of the presence or
absence of the FUS1 3’UTR. NCI-H1299 cells were transfected with equal amounts (0.46 nM)
of either constructs expressing Flag-FUS1, Flag-FUS1-3’UTR or empty vector (control),
respectively. Colonies were visualized by staining with 1% crystal violet (E). Quantification
of (F) number of colonies and (G) total area of colonies was from three independent colony
formation assays. (**, p<0.01; ***, p<0.001)
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Figure 2. miR-93, miR-98 and miR-197 are predicted to target FUS1
(A) The FUS1 gene structure, showing the predicted target sites of each miRNA and the
conservation of the 3’UTR across species. (B) The structure of the miRNA:target interactions
for miR-197, miR-93, and miR-98, with the sequence of the miRNA, the sequence of the target
site and the predicted free energy of hybridization. The seed sequence is highlighted in red.
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Figure 3. miR-93, miR-98 and miR-197 translationally repress FUS1
(A–D) NCI-H1299 cells were plated in 100 mm dishes and co-transfected with Flag-
FUS1-3’UTR expression vector (2 µg) and either pCMV6 empty vector (control) or pCMV6/
miRNA expression vectors (10 µg), respectively, using Lipofectamine 2000 transfection
reagent. After 48 h cell lysates were harvested and total RNA was isolated. Fus1 expression
levels (A, B) were measured by Western blot using an anti-Flag antibody. Calnexin levels were
used as a loading control. Quantification results were from three independent experiments.
Relative levels of FUS1 (C) and neo (D) mRNAs, as well as miRNA levels (E) were measured
by qRT-PCR. (F) The 3’UTR of FUS1 was cloned into a reporter construct containing a
luciferase cDNA under the control of a mammalian promoter/terminator system. HEK-293
cells were plated in 24-well plates and co-transfected with pMIR-REPORT/luciferase-FUS1
3’UTR (0.4 µg), pCMV6/miRNAs (0.4 µg or 2 µg) and pMIR-REPORT/β gal control
expression constructs (0.8 µg) using FuGENE 6 Transfection Reagent. After 48 h of
transfection, cells were lysed and luciferase and β-galactosidase activity were measured.
Shown are normalized luciferase activity for miR-93, miR-98 and miR-197, with miR-199b
and an empty vector (pCMV6) as negative controls. The concentrations are of the transfected
miRNA expression vector, and are 1X and 5X relative to that of the transfected luciferase
reporter construct. (*, p<0.05; **, p<0.01).
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Figure 4. Deletion of the target sites of the three miRNAs restores Fus1 protein expression levels
in NCI-H1299 cells
NCI-H1299 cells were transfected with equal amounts (0.46 nM) of vectors expressing Flag-
FUS1, wildtype Flag-FUS1-3’UTR and several mutated versions of Flag-FUS1-3’UTR, in
which the seed sequences of the target sites in the FUS1 3’UTR are deleted, using
Lipofectamine 2000 transfection reagent. After 48 h cell lysates were harvested and Fus1
expression levels (A,B) were measured by Western blot using an anti-Flag antibody. Calnexin
levels were used as a loading control. The quantitation was generated from two independent
transfections, each with two repeated Western blots. Relative levels of FUS1 mRNA (C) and
neo mRNA (D) were measured by qRT-PCR. (E–G) Colony formation as a function of the
Fus1 protein. NCI-H1299 cells were transfected with equal amounts (0.46 nM) of the above
constructs. Colonies were visualized and quantified as described previously. (*, p<0.05; **,
p<0.01; ***, p<0.001).
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Figure 5. miR-93, miR-98 and miR-197 are differentially expressed among SCLC, NSCLC, and
HBEC cell lines
(A) Expression levels of miR-93, miR-98 and miR-197 across the panel of cell lines. The
expression levels have been normalized by subtracting the mean expression and dividing by
the standard deviation. Red represents miRNAs that are over-expressed relative to the
reference; blue represents miRNAs that are under-expressed. (B) The mean expression levels
of miR-93, miR-98 and miR-197 by group. Significance was assessed by two-tailed t-test.
SCLC and (S), small-cell lung cancer; NSCLC and (N), non-small-cell lung cancer. (*, p<0.05;
**, p<0.01; ***, p<0.001).
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Figure 6. Expression of miR-93 and miR-197 is inversely correlated with Fus1 expression in lung
cancer tumor specimens
miR-93, miR-98 and miR-197 levels were measured in 6 squamous cell carcinoma and 14
adenocarcinoma tumor specimens. The 20 samples were divided into two groups of 10
specimens, the low Fus1 group and the high Fus1 group, based on Fus1 protein expression
levels measured by immunohistochemical staining. Significance was assessed by one-sided t-
test. (*, p<0.05).
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